Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750958 · ClinicalTrials.gov registry record · NA
PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard
A NA study of Cardiac Event, sponsored by Datascope Patient Monitoring.
- Completed
- Registry status
- NA
- Development phase
- 287
- Enrollment target
- 2
- Study locations
NCT00750958: Completed NA study of Cardiac Event, sponsored by Datascope Patient Monitoring.
NCT00750958 is a NA study of Cardiac Event that has completed, run by Datascope Patient Monitoring. The registered enrollment target is 287 participants, below the 993-participant average among 3 other Cardiac Event trials with a reported enrollment target (71% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00750958, a NA study of Cardiac Event, has completed, sponsored by Datascope Patient Monitoring.
- COMPLETED
- Registry status
- NA
- Development phase
- 287 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine the incidence of clinically significant rhythm and rate changes in ED patients who are not placed on conventional telemetry, and to test the user-friendliness of a automated clinician alter device in hectic and noisy setting of a busy emergency room.
Conditions Studied
Interventions
- PROCEDURE NetGuard Automated Clinician Alert System
Study Locations (2)
Pennsylvania
- Dr Charles Pollack - Philadelphia
- University of Pennsylvania - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 287 participants |
| Start Date | 2008-06 |
| Est. Completion | 2008-07 |
| Phase | NA |
What the finished NCT00750958 record still lists
NCT00750958 is an interventional study that assigns participants to a tested intervention. The registered 287 participants enrollment target is mid-sized for trials with a published cap, below the 993-participant average among 3 other Cardiac Event trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Cardiac Event appearing as the primary indexed condition, and to 1 intervention - of which NetGuard Automated Clinician Alert System is the first listed.
NCT00750958 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT00750958 about?
NCT00750958 is a clinical study titled "PREVENT - Prospective Rhythm Event Surveillance in the ER With NetGuard". The purpose of this study is to determine the incidence of clinically significant rhythm and rate changes in ED patients who are not placed on conventional telemetry, and to test the user-friendliness of a automated clinician alter device in hectic and noisy setting of a busy emergency room.
What is the current status of trial NCT00750958?
This trial is currently completed. It is a NA study. The enrollment target is 287 participants. The study started on 2008-06. Estimated completion is 2008-07.
What conditions does trial NCT00750958 study?
This clinical trial studies the following conditions: Cardiac Event.
What interventions are being tested in trial NCT00750958?
The interventions under investigation include: NetGuard Automated Clinician Alert System (PROCEDURE).
Who is sponsoring clinical trial NCT00750958?
This trial is sponsored by Datascope Patient Monitoring, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00750958 being conducted?
This trial has 2 study locations across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiac Event
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03094429 · 287 participants · Phase 2
An Adaptive Phase II/III, Two-Part, Double-Blind, Randomized, Placebo-controlled, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults
- NCT06385080 · 287 participants · Phase 1
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
- NCT06919224 · 287 participants · NA
Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- NCT02098265 · 288 participants · NA
A Closed Loop Neural Activity Triggered Stroke Rehabilitation Device
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia